0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Oncovista Innovative Therapies
Its shares trade under the ticker OVIT. It has been listed since 23 January 2006.
OncoVista Innovative Therapies, Inc. is a drug development company, which engages in the development and commercialization of targeted cancer therapies. The company is headquartered in San Antonio, Texas. The company went IPO on 2006-01-23. The firm is engaged in developing targeted anticancer therapies by utilizing tumor-associated biomarkers. The firm's product pipeline consists of advanced (Phase II) and early (Phase I) clinical-stage compounds, late preclinical drug candidates and early preclinical leads. The firm's therapeutic strategy is based on targeting the patient's tumors with treatments that will deliver drugs selectively based upon specific biochemical characteristics of the cancer cells comprising the tumor. The firm's products include: Cordycepin (OVI-123) and L-Nucleoside Conjugates (OVI-117). Cordycepin depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for its therapeutic activity. OVI-117 is a thymidylate synthase (TS) inhibitor with pharmacological properties, which results in a retention of efficacy and a reduction of toxicity.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Jan 2006
- Employees
- 3
Leadership
Pay as last reported
- Dr. Alexander WeisChairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Secretary, since 2007$322,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Unique Therapies: Oncovista Innovative Therapies Inc has developed innovative and unique therapies that differentiate it from competitors, providing a competitive advantage in the market.
- Strong Research and Development: The company invests heavily in research and development, allowing them to continuously enhance their therapies and stay at the forefront of technological advancements.
- Established Partnerships: Oncovista has established strategic partnerships with renowned research institutions and medical centers, fostering collaboration and knowledge exchange.
Weaknesses
- Limited Market Presence: Oncovista's market presence is relatively small, limiting its ability to reach a broader customer base and generate significant sales.
- Dependency on Funding: The company heavily relies on external funding sources, such as investments and grants, which may pose challenges during economic downturns or industry volatility.
- Regulatory Challenges: Obtaining regulatory approvals for new therapies can be time-consuming and costly, potentially delaying product launches and revenue generation.
Opportunities
- Increasing Demand for Innovative Therapies: With a growing emphasis on personalized medicine and advanced treatments, the demand for Oncovista's innovative therapies is expected to increase in the market.
- Collaborative Partnerships: Exploring additional partnerships with pharmaceutical companies and healthcare organizations can expand Oncovista's reach and help in commercializing their therapies more effectively.
- Emerging Markets: Expansion into emerging markets provides the opportunity to tap into untapped patient populations and increase revenue streams.
Threats
- Intense Competition: The biotech industry is highly competitive, with numerous companies competing for market share, which may put pressure on Oncovista's pricing and ability to attract customers.
- Intellectual Property Protection: Protecting intellectual property rights is critical in the biotech sector. Any breach or infringement by competitors may negatively impact Oncovista's competitive advantage and market position.
- Regulatory and Compliance Risks: The healthcare industry is subject to complex regulations and compliance standards. Non-compliance can result in legal and financial consequences, potentially affecting Oncovista's operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.